13/02/2010 - 12:30 - 14:30 Poster Session 2 Sessione Poster SP2 SP.02.1 THE CLINICAL SIGNIFICANCE OF SCLERODERMA-RELATED AUTOANTIBODIES IN 19 28 CHINESE SYSTEMIC SCLEROSIS PATIENTS. Q. WANG, D. XU, MT. LI, Y. HOU, XF. ZENG, JL. ZHAO SP.02.1 COEXISTING ANTITOPOISOMERASE I AND ANTICENTROMERE ANTIBODIES IN 20 29 SYSTEMIC SCLEROSIS: A EUSTAR GROUP-BASED STUDY U. WALKER, A. Tyndall, V. Smith, A. Simsek, M. Becker, M. Vanthuyne, T. Minier, P. Carreira, P. Tuvik, R. Caporali, I. Heijnen SP.02.1 CLONAL T CELL POPULATIONS ARE FREQUENT IN THE SKIN AND BLOOD OF 53 30 PATIENTS WITH SYSTEMIC SCLEROSIS G. RENATA, C. Tigges, S. Höxtermann, S. A. Hahn, P. Altmeyer, T. Gambichler, A. Kreuter SP.02.1 RAISED INTERLEUKIN-4 AND INTERLEUKIN-17 SERUM LEVELS IN PATIENTS WITH 100 31 SYSTEMIC SCLEROSIS R.C. Ionitescu, R. Sfrent-Cornateanu, C. Mihai, M. Bojinca, L. Macovei, C. Ciofu, C. Mogosan, O. Manea, M. Sasu, I. Ancuta, S. Tanaseanu, C. Baicus, O. Dragoescu, M. Abobului, D. Predetean, R. Ionescu, V. Stoica SP.02.1 ANTI-CENP-A AND ANTI-CENP-B ANTIBODIES SHOW HIGH CONCORDANCE AND 164 32 SIMILAR CLINICAL ASSOCIATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS DESPITE COMPLETELY DIFFERENT UNDERLYING PROTEIN SEQUENCES. K. HANKE, C.S. Brueckner, M. Becker, W. Meyer, W. Schlumberger, G.R. Burmester, G. Riemekasten SP.02.1 ANTI-RNA POLYMERASE III ANTIBODIES AND SCLERODERMA RENAL CRISIS: 185 33 EVALUATION OF A FRENCH COHORT S. EMILIE, C. GOULVESTRE, A. BEREZNE, C. PAGNOUX, L. GUILLEVIN, L. MOUTHON SP.02.1 AUTOANTIBODY PROFILE IN A COHORT OF 475 ITALIAN SCLERODERMA 224 34 PATIENTS. A. CERIBELLI(,,,), I. CAVAZZANA, S. ZINGARELLI, M. SCARSI, P. AIRO', A. TINCANI(,), F. FRANCESCHINI, B.A. PAULEY, E.K.L. CHAN, M. SATOH Page 17
SP.02.1 THE CLINICAL SIGNIFICANCE OF SCLERODERMA-RELATED AUTOANTIBODIES IN 19 28 CHINESE SYSTEMIC SCLEROSIS PATIENTS.
Q. WANG, D. XU, MT. LI, Y. HOU, XF. ZENG, JL. ZHAO
SP.02.1 COEXISTING ANTITOPOISOMERASE I AND ANTICENTROMERE ANTIBODIES IN 20 29 SYSTEMIC SCLEROSIS: A EUSTAR GROUP-BASED STUDY
U. WALKER, A. Tyndall, V. Smith, A. Simsek, M. Becker, M. Vanthuyne, T. Minier, P. Carreira, P. Tuvik, R. Caporali, I. Heijnen
SP.02.1 CLONAL T CELL POPULATIONS ARE FREQUENT IN THE SKIN AND BLOOD OF 53 30 PATIENTS WITH SYSTEMIC SCLEROSIS
G. RENATA, C. Tigges, S. Höxtermann, S. A. Hahn, P. Altmeyer, T. Gambichler, A. Kreuter
SP.02.1 RAISED INTERLEUKIN-4 AND INTERLEUKIN-17 SERUM LEVELS IN PATIENTS WITH 100 31 SYSTEMIC SCLEROSIS
R.C. Ionitescu, R. Sfrent-Cornateanu, C. Mihai, M. Bojinca, L. Macovei, C. Ciofu, C. Mogosan, O. Manea, M. Sasu, I. Ancuta, S. Tanaseanu, C. Baicus, O. Dragoescu, M. Abobului, D. Predetean, R. Ionescu, V. Stoica
SP.02.1 ANTI-CENP-A AND ANTI-CENP-B ANTIBODIES SHOW HIGH CONCORDANCE AND 164 32 SIMILAR CLINICAL ASSOCIATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS DESPITE COMPLETELY DIFFERENT UNDERLYING PROTEIN SEQUENCES.
K. HANKE, C.S. Brueckner, M. Becker, W. Meyer, W. Schlumberger, G.R. Burmester, G. Riemekasten
SP.02.1 ANTI-RNA POLYMERASE III ANTIBODIES AND SCLERODERMA RENAL CRISIS: 185 33 EVALUATION OF A FRENCH COHORT
S. EMILIE, C. GOULVESTRE, A. BEREZNE, C. PAGNOUX, L. GUILLEVIN, L. MOUTHON
SP.02.1 AUTOANTIBODY PROFILE IN A COHORT OF 475 ITALIAN SCLERODERMA 224 34 PATIENTS.
A. CERIBELLI(,,,), I. CAVAZZANA, S. ZINGARELLI, M. SCARSI, P. AIRO', A. TINCANI(,), F. FRANCESCHINI, B.A. PAULEY, E.K.L. CHAN, M. SATOH
Page 17
SP.02.1 ANTI-TH/TO ANTIBODIES IN ITALIAN SCLERODERMA PATIENTS: CLINICAL AND 225 35 IMMUNOLOGICAL CORRELATIONS AND COMPARISON WITH PATIENTS WITH ANTI-CENTROMERE (ACA) ANTIBODIES A. CERIBELLI, I. CAVAZZANA, P. AIRO', A. TINCANI(,), F. FRANCESCHINI, B.A. PAULEY, E.K.L. CHAN, M. SATOH
SP.02.1 PREVALENCE OF ANTIBODIES ASSOCIATED TO PRIMARY BILIARY CIRRHOSIS IN 226 36 PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS
I. CAVAZZANA, M. TARABORELLI, A. CERIBELLI, P. AIRO', R. CATTANEO, A. TINCANI, F. FRANCESCHINI
SP.02.1 DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS WITH ANTICENTROMERE 234 38 ANTIBODIES
BE. Joven, L. Carmona, PE. Carreira
SP.02.1 AB0413] THE DETERMINATION OF ANTI-TOPOISOMERASE I, ANTI-CENP-B AND 236 39 ANTI-RNA POLYMERASE III AUTOANTIBODIES BY ELISA AND COMPARISON WITH CLINICAL PARAMETERS IN SYSTEMIC SCLEROSIS
Y. CAGATAY, N. GUREL-POLAT, B. ARTIM-ESEN, S. KAMALI, A. GUL, L. OCAL, M. KONICE, O. ARAL, M. INANC
SP.02.1 ANTI-IFI16 AUTOANTIBODIES: A NEW MARKER IN SYSTEMIC SCLEROSIS 298 40
M. Mondini, S. Costa(,), V. Caneparo, M. Gariglio(,), S. Landolfo(,), THE. FIRMA co-authors
SP.02.1 PHOSPHORYLATION OF PDGFR IN SKIN BIOPSIES OF PATIENTS WITH 304 41 SCLERODERMA
K. PHILLIPS, E. Schiopu, R. Maher, R. Mathews, S. McDonald, Z. Stewart, M. Gerber, A. Impens, J.R. Seibold
SP.02.1 ANTI-RNA POLYMERASE III ANTIBODIES ARE ASSOCIATED WITH PROXIMAL SKIN 331 42 INVOLVEMENT, INCREASED RISK OF RENAL CRISIS AND ANEMIA IN A FRENCH COHORT OF SYSTEMIC SCLEROSIS PATIENTS
S. EMILIE, C. GOULVESTRE, A. BEREZNE, C. PAGNOUX, L. GUILLEVIN, L. MOUTHON
Page 18
SP.02.1 DECREASED SERUM IL-7 LEVELS IN PATIENTS WITH SYSTEMIC SCLEROSIS 366 43 TAKAMITSU. Makino, SATOSHI. Fukushima, SHOJI. Wakasug, HIRONOBU. Ihn
SP.02.1 OSTEOPENIC SYNDROME IN SYSTEMIC SCLEROSIS 7 44
R. YATSYSHYN, YE. NEYKO, N. YATSYSHYN
SP.02.1 BONE MINERAL DENSITY PARAMETERS IN A GROUP OF FEMALE PATIENTS WITH 40 45 SYSTEMIC SCLEROSIS
K. SIMIC PASALIC, N. DAMJANOV, N. PILIPOVIC, N. GAVRILOV, J. PETRIC
SP.02.1 BONE MINERAL DENSITY AND MICROVASCULAR DAMAGE IN SYSTEMIC 44 46 SCLEROSIS PATIENTS
B. SERIOLO, C. PIZZORNI, A. CASABELLA, C. FERRONE, S. PAOLINO, A. SULLI, M. CUTOLO
SP.02.1 ASSESSMENT OF CLINICAL RISK FACTORS OF OSTEOPOROSIS AND BONE 223 47 MINERAL DENSITY IN SYSTEMIC SCLEROSIS
A. THEULIN, J.E. GOTTENBERG, E. CHATELUS, R.M. JAVIER, J. SIBILIA
SP.02.1 TWO IL-6 GENE POLYMORPHISMS IN SYSTEMIC SCLEROSIS: A MULTICENTER 43 48 EUSTAR STUDY
R. SFRENT-CORNATEANU, Y. Allanore, D. Opris, C. Mihai, O. Popa, R. Ionitescu, C. Bara, R. Ionescu, N. Hunzelmann, V. Schlossberg, S. Guiducci, V. Rogai, V. Riccieri, P. Caramaschi, M. Pileckyte, D. Krasowska, M. Michalska-Jakubus, M. Matucci-Cerinic
SP.02.1 THE GENE POLYMORPHISM WITHIN HEPATOCYTE GROWTH FACTOR PROMOTER 47 49 CONTROLS PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
T. SATOH, K. HOSHINO, M. KUWANA
SP.02.1 ANALYSIS OF POLYMORPHISMS IN THE HOMEOBOX TRANSCRIPTION FACTOR 180 50 NKX2-5 GENE IN PATIENTS WITH SYSTEMIC SCLEROSIS
M. Zolnowska, M. PONTICOS, P. PANTELIDIS, CP. DENTON, D. ABRAHAM, C. FONSECA
Page 19
SP.02.1 PHENOTYPE-HAPLOTYPE CORRELATION OF IRF5 GENE IN SSC: ASSOCIATION 197 51 WITH DIFFERENT FIBROTIC SUB-PHENOTYPES P. DIEUDE, K. DAWIDOWICZ, M. GUEDJ, C. BOILEAU, Y. ALLANORE(.), and GFRS co-workers
SP.02.1 BANK1 IS A GENETIC RISK FACTOR FOR DIFFUSE CUTANEOUS SYSTEMIC 198 52 SCLEROSIS HAVING ADDITIVE EFFECTS WITH IRF5 AND STAT4
P. DIEUDE, M. GUEDJ, J. WIPPF, I. MELCHERS, C. BOILEAU, Y. ALLANORE(,), GFRS and DNSS co-workers
SP.02.1 STUDDING THE INFLUENCE OF PTPN22 GENE IN SYSTEMIC SCLERODERMA 199 53
L. DIAZ-GALLO, P. Gourh, J. Broen, ECSG, TRDJ. Radstake, MD. Mayes, FC. Arnett, J. Martin, B. Rueda
SP.02.1 ASSOCIATION OF CR2/CD21 POLYMORPHISMS WITH SYSTEMIC SCLEROSIS 246 54
C. BONINO, M. ZORZETTO, S. OTTAVIANI, L. CAVAGNA, E. PARACCHINI, E. POZZI, A. DE SILVESTRI, C. MONTECUCCO, M. LUISETTI
SP.02.1 THE FAS -670A>G POLYMORPHISM INFLUENCES THE SUSCEPTIBILITY TO 301 55 SYSTEMIC SCLEROSIS PHENOTYPES
J. Broen, P. Gourgh, B. Rueda, R. Hesselstrand, A. Herrick, J. Worthington, S. Agarwal, F. Tan, C. Denton, Fonseca, G. Riemekasten, M. Vonk, H. Kiener, Scorza, L. Beretta, M. Coenen, M. Mayes, J. Martin, F. Arnett, T. Radstake
SP.02.1 RESULTS FROM A EUSTAR BASED STUDY: FUNCTIONAL VARIANTS OF FCgRIIA 356 56 AND FCgRIIIA ARE NOT ASSOCIATED WITH SSC SUSCEPTIBILITY OR CLINICAL PHENOTYPE.
Z ALIDEH. Behrooz, J. Broen, B. Rueda, R. Hesselstrand, A. Herrick, J. Worthington, C. Denton, Fonseca, G. Riemekasten, MC. Vonk, FHJ. van den Hoogen(), M. Matucci-Cerenic(), Scorza(), L. Beretta(), P. Airo(), M. Coenen(), J. Martin(), BPC. Koeleman(), TRDJ. Radstake()
SP.02.1 GLOBAL GENE EXPRESSION PROFILING OF SCLERODERMA LUNG FIBROBLASTS 357 57 IDENTIFIES CONSISTENT DOWNREGULATION OF INTERFERON RELATED GENES
E. RENZONI, X. Shi-Wen, S. Howat, G. Lindhal, P. Sestini, RM. du Bois, AU. Wells, DJ. Abraham
SP.02.1 ASSOCIATION OF A FUNCTIONAL POLYMORPHISM IN THE MMP12 PROMOTER 367 58 REGION WITH SYSTEMIC SCLEROSIS
M. Manetti(,), L. Ibba-Manneschi, C. Fatini, S. Guiducci, A.F. Milia, S. Bombardieri, CM. Montecucco, R. Abbate, R. Giacomelli, G. Valentini, M. Matucci-Cerinic
Page 20
SP.02.1 THE FREQUENCY OF GASTROINTESTINAL INVOLVEMENT IN 75 ROMANIAN 29 59 PATIENTS WITH SYSTEMIC SCLEROSIS M. TAMAS, C. PAMFIL, I. FILIPESCU, C. BOLOSIU, D. DUMITRASCU(,), S. REDNIC(,)
SP.02.1 ERADICATION OF HELICOBACTER PYLORI MAY REDUCE DISEASE SEVERITY IN 54 60 SYSTEMIC SCLEROSIS
M. RADIC, D. Martinovic Kaliterna, D. Bonacin
SP.02.1 ANORECTAL PHYSIOLOGY AND MORPHOLOGY IN SYSTEMIC SCLEROSIS 179 61 PATIENTS WITH AND WITHOUT FAECAL INCONTINENCE
K. FRANCK-LARSSON, W. GRAF, K. EDEBOL-EEG OLOFSSON, H. AXELSON, A. RÖNNBLOM
SP.02.1 RADIONUCLIDE ESOPHAGEAL TRANSIT SCINTIGRAPHY IN SYSTEMIC SCLEROSIS: 238 62 ASSOCIATION WITH CLINICAL AND LABORATORY FEATURES.
M. BREDEMEIER, M. Viter da Rosa Barbosa, A. Ferrari, F. Sabadin Bertol, G. Horta, R. Kupske, V. Greg¨®rio Restelli, E. Hennemann Pitrez, M. Vasconcelos Vieira, J. Tavares Brenol, R. Machado Xavier
SP.02.1 ASSOCIATION BETWEEN ESOPHAGEAL DILATATION ON CHEST HIGH RESOLUTION 239 63 COMPUTED TOMOGRAPHY (HRCT) AND CLINICAL ABNORMALITIES IN SYSTEMIC SCLEROSIS.
M. BREDEMEIER, G. Horta, R. kupske, M. Viter da Rosa Barbosa, A. Ferrari, F. Sabadin Bertol, E. Hennemann Pitrez, M. Vasconcelos Vieira, J. Tavares Brenol, R. Machado Xavier
SP.02.1 SYSTEMIC SCLEROSIS AND NUTRITIONAL STATUS 247 64
C. BONINO, L. CAVAGNA, B. XOXI, R. CACCIALANZA, M. MARINELLI, A. CRIPPA, M. ORLANDI, M. RAVA, R. CAPORALI, C. MONTECUCCO
SP.02.1 EVALUATION OF HEPATIC FIBROSIS WITH TRANSIENT ELASTOGRAPHY 254 65 (FIBROSCAN) AND APRI SCORE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ITS CORRELATION WITH PULMONARY, CARDIAC, RENAL AND ESOPHAGEAL INVOLVEMENT
M. BASSO, A. Picciotto, S. Blanchi, G. Filaci, F. Indiveri, S. Negrini, N. Panico, M. Setti, M. Ghio
SP.02.1 LACTULOSE BREATH TEST IS A NON-INVASIVE TOOL TO ASSESS ESOPHAGEAL 308 66 INVOLVEMENT IN SCLERODERMA PATIENTS
N. PANICO, S. NEGRINI, A. PARODI, E. SAVARINO, F. INDIVERI, M. GHIO
Page 21
SP.02.1 RIGHT VENTRICULAR DIASTOLIC FUNCTION IN PATIENTS WITH SYSTEMIC 1 67 SCLEROSIS M. ZLATANOVIC, B. IVANOVIC, M. TADIC, N. DAMJANOV, R. PETROVIC
SP.02.1 MYOCARDIAL INTEGRATED BACKSCATTER ANALYSIS (IBS) IN SYSTEMIC 56 68 SCLEROSIS (SSC): RELATION WITH CLINICAL AND ECHOCARDIOGRAPHIC FEATURES.
E. Banfi, G. Erba, A.C.M. Capra, E. Allevi, M. Riva, M. Ricci, C. Giannattasio, R. Facchetti, M.R. Pozzi, G. Mancia
SP.02.1 ECHOCARDIOGRAPHIC PREDICTORS OF ELEVATED B-TYPE NATRIURETIC 201 73 PEPTIDE IN SYSTEMIC SCLEROSIS
C. DESAI, M. Hinchcliff, J. Varga, S.J. Shah
SP.02.1 PREDICTING FACTORS FOR ARRHYTHMIA AND HEART CONDUCTION BLOCK IN 241 74 SYSTEMIC SCLEROSIS PATIENTS
Y. BRAUN-MOSCOVICI, M. BRAUN, AM. NAHIR, A. BALBIR-GURMAN
SP.02.1 TAKO-TSUBO-LIKE SYNDROME: A MANIFESTATION OF MICROVASCULAR 263 75 INVOLVEMENT IN SYSTEMIC SCLEROSIS?
M. Battellino, M. Antivalle, A. Batticciotto, L. Bertani, A. Mutti, F. Atzeni, PC. Sarzi-Puttini
Page 22
SP.02.1 N-TERMINAL PRO BRAIN NATRIURETIC PEPTIDE IN SYSTEMIC SCLEROSIS: A NEW 270 76 CORNERSTONE FOR CARDIOVASCULAR ASSESSMENT Y. ALLANORE, DIDIER. Borderie, ANDRÉ. Kahan, CHRISTOPHE. Meune
SP.02.1 DIAGNOSTIC AND PROGNOSTIC VALUE OF COMBINED FUNCTIONAL TESTS FOR 291 77 CORONARY MICROCIRCULATION INVOLVEMENT IN SYSTEMIC SCLEROSIS.
A. VACCA, R. MONTISCI, P. GARAU, P. SIOTTO, A. CAULI, M. RUSCAZIO, L. MELONI, S. ILICETO, A. MATHIEU
SP.02.1 HEART INVOLVEMENT IN SYSTEMIC SCLERODERMA PRIMARILY INVOLVES THE 312 78 RIGHT HEART AND AFFECTS BOTH MAJOR SSC SUBSETS
M. MEURER, P. Rehberger, C. Pfeiffer, F. Walz, R. Strasser
SP.02.1 IMPLANTABLE CARDIOVERTER DEFIBRILLATOR TO PREVENT ARRYTHMIC DEATH 338 79 IN SCLERODERMIC CARDIOMYOPATHY.
SP.02.1 ACUTE CORONARY SYNDROME IN SYSTEMIC SCLEROSIS DURING TREATMENT 345 80 WITH PROSTANOIDS: CLINICAL AND ANGIOGRAPHIC CORRELATES
M. ANTIVALLE, M. BATTELLINO, A. BATTICCIOTTO, L. BERTANI, A. MUTTI, F. ATZENI, PC. SARZI-PUTTINI
SP.02.1 CHARACTERIZATION OF IN VITRO PROPERTIES OF MESENCHYMAL STEM CELLS 213 81 FROM BONE MARROW OF PATIENTS WITH SYSTEMIC SCLEROSIS: PROMISING FEATURES FOR SSC ANTI-FIBROTIC STRATEGIES
N. DEL PAPA, N. Quirici, C. Scavullo, L. Corti, M. Introna, W. Maglione, D.P. Comina, N. Vaso, F. Onida, G. Lambertenghi Deliliers
SP.02.1 DIFFERENTIATION RESPONSES OF BONE MARROW DERIVED MESENCHYMAL 341 82 STEM CELLS FROM SYSTEMIC SCLEROSIS PATIENTS TO PRO-FIBROTIC CYTOKINES
B. Hegner, R. Catar, A. Kusch, K. Essin, M. Naether, M. Gollasch, G. Riemekasten, D. Dragun
SP.02.1 IMMUNE RECONSTITUTION AND LYMPHOCYTE SUBPOPULATIONS AFTER 375 83 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS
M.S. Wagner, J. Henes, W. Vogel, U. Holzer, M. Haug, L. Kanz, I. Kötter
Page 23
SP.02.1 INDUCED SPUTUM AS A METHOD FOR DETECTION OF SYSTEMIC SCLEROSIS 6 84 RELATED INTERSTITIAL LUNG DISEASE N. YILMAZ, Y. ABUL, M. BIÇAKCIGIL, P. GOLABI, C. CELIKER, S. KARAKURT, S. YAVUZ
SP.02.1 HOMOCYSTEINE BLOOD LEVEL IN SYSTEMIC SCLEROSIS PATIENTS – 38 85 ASSOCIATION WITH IMPAIRMENTS OF THE RESPIRATORY SYSTEM
L. Shvets, M. Stanislavchuk
SP.02.1 GRANULOCYTOSIS IN INDUCED SPUTUM IS LINKED TO INTERSTITIAL LUNG 71 86 FIBROSIS AND RESTRICTIVE LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
P. OSTOJIC, N. Damjanov, O. Kaloudi, S. Alari, F. Porta, M. Cinelli, S. Guiducci, V. Rogai, G. Camiciottoli, E. Meoni, M. Matucci-Cerinic
SP.02.1 PULMONARY INVOLVEMENT IN CHINESE PATIENTS WITH SSC AND 119 87 CORRELATIONS BETWEEN THE IMAGING AND FUNCTIONAL ABNORMALITIES
M. PENG, W. XU, Q. WANG, J. ZHAO, M. LI, D. XU, Y. HOU, X. ZENG
SP.02.1 ANTI-MOESIN ANTIBODY: AN EARLY PREDICTOR FOR SYSTEMIC SCLEROSIS 122 88 ASSOCIATED INTERSTITIAL LUNG DISEASE
M. LI, J. ZHAO, Q. WANG, D. XU, Y. HOU, X. ZENG
SP.02.1 PULMONARY FUNCTIONAL IMPAIRMENT WITH ISOLATED LOW TRANSFER FACTOR 131 89 IN SYSTEMIC SCLEROSIS
I. FABREGUET, K. KUET, M. AKIL, R. KILDING, D. KIELY
SP.02.1 PULMONARY FUNCTION TESTING PARAMETERS AND AEROBIC EXERCISE 244 90 CAPACITY IN SUBJECTS WITH SCLERODERMA
AK. Boutou, P. Siakka, T. Dimitroulas, T. Sfetsios, G. Pitsiou, C. Nakou, P. Argyropoulou, A. Garyfallos, I. Stanopoulos
SP.02.1 ULTRASOUND LUNG COMETS AS A LONG-TERM PROGNOSTIC DETERMINANT IN 252 91 SYSTEMIC SCLEROSIS
SP.02.1 TUBERCULOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: TRIGGER, MIMICKER 267 93 AND INTERFERENCE WITH TREATMENT S. ANANDAN, S. Shobana, Sharmatha, T P. Vetrichevvel, L. Renita, Adikrishnan
SP.02.1 INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS 277 94
A. ABDESSEMED, N. KHALDOUN, N. BRAHIMI, A. LADJOUZE
SP.02.1 DIFFERENT FORMS OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS AND 280 95 THEIR CLINICAL ASSOCIATIONS– DATA FROM THE GERMAN SYSTEMIC SCLEROSIS NETWORK REGISTRY (DNSS)
M. BECKER, D. Huscher, C. Brueckner, K. Hanke, DNSS centres, G.R. Burmester, G. Riemekasten
SP.02.1 ROLE OF 18F-FDG PET/CT TO ASSESS ACTIVITY AND EXTENSION OF LUNG 314 96 INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS.
ANDREA. LO MONACO, RENATO. LA CORTE, NAPOLEONE. PRANDINI, VALENTINA. De CRISTOFARO, SARA. FABBRI, LUCIANO. FEGGI, FRANCESCO. TROTTA
SP.02.1 STRESS AND REST CARDIAC-CHEST ULTRASOUND IN SYSTEMIC SCLEROSIS 323 97
L. GARGANI, A. MOREO, G. AGOSTON, M. DOVERI, ML. BAZZICHI, O. EPIS, M. MUSCARA', S. CATALDO, E. BRUSCHI, B. CANESI, O. PARODI, R. SICARI, A. VARGA, S. BOMBARDIERI, E. PICANO
SP.02.1 ULTRASOUND LUNG COMETS IN SYSTEMIC SCLEROSIS: A CHEST SONOGRAPHY 324 98 HALLMARK OF PULMONARY INTERSTITIAL FIBROSIS
L. GARGANI, M. DOVERI, L. D'ERRICO, F. FRASSI, ML. BAZZICHI, A. DELLE SEDIE, MC. SCALI, S. MONTI, S. MONDILLO, S. BOMBARDIERI, D. CARAMELLA, E. PICANO
SP.02.1 STUDY ON SOME LUNG FUNCTION PARAMETERS IN PATIENTS WITH SYSTEMIC 352 99 SCLEROSIS IN NORTH-EAST PART OF POLAND
J. Fryc, P. Siergiejko, K. Tytman, Z. Siergiejko, E. Gindzienska-Sieskiewic, J. Rojewska, S. Sierakowski
SP.02.2 LOW INCIDENCE OF SCLERODERMA RENAL CRISIS IN A COHORT OF 901 115 00 PATIENTS WITH SYSTEMIC SCLEROSIS
R.G. MARANGONI, L.F. ROCHA, A.P.T. DEL RIO, N.H. YOSHINARI, J.F. MARQUES-NETO, P.D. SAMPAIO-BARROS
SP.02.2 NEPHROGENIC SYSTEMIC FIBROSIS: A CASE STUDY FROM DENMARK 186 01
T. ELMHOLDT, B. JØRGENSEN, M. RAMSING, J.D. JENSEN, K. SØNDERGAARD, M. PEDERSEN, A.B. OLESEN
Page 25
SP.02.2 INFLUENCE OF APL POSITIVITY ON GLOMERULAR FILTRATION RATE MARKERS 194 02 IN A GROUP OF SYSTEMIC SCLEROSIS PATIENTS – 24 MONTHS OBSERVATION M. Majdan, E. Wielosz, M. Dryglewska
SP.02.2 SCLERODERMA RENAL CRISIS. A RETROSPECTIVE MULTICENTER STUDY IN 91 284 03 PATIENTS AND 456 CONTROLS.
L. GUILLEVIN, A. BEREZNE, R. SEROR, L. TEIXEIRA, JJ. POURRAT, A. MAHR, E. HACHULLA, C. HAGARD, J. CABANE, P. VANHILLE, JR. HARLE, I. DELEVEAUX, L. MOUTHON
SP.02.2 LONG-TERM EFFECTS OF ALPROSTADIL AT THE CYTOKINE PRODUCTION IN 8 04 SCLERODERMA PATIENTS
R. YATSYSHYN, YE. NEYKO, N. YATSYSHYN
SP.02.2 COMBINATION WITH BOSENTAN AND BERAPROST FOR THE TREATMENT OF 10 05 PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
Y. YAMASAKI, H. YAMADA, M. OMATA, S. OZAKI
SP.02.2 TRANSIENT SIGNIFICANT IMPROVEMENT IN ORGAN FUNCTION IN A PATIENT WITH 13 06 SYSTEMIC SCLEROSIS TREATED WITH AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION
M. WIDUCHOWSKA, A. Kotulska, M. Kopec-Medrek, M. Biedron-Machura, W. Pierzchala, E.J. Kucharz
SP.02.2 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS 31 07 WITH SYSTEMIC SCLEROSIS – THE FIRST EXPERIENCES FROM HUNGARY
S. Szamosi, L. Varoczy, A. Illes, A. Kiss, Z. Szekanecz, G. Szucs
SP.02.2 DENIALS OF TREATMENT COVERAGE BY HEALTH INSURANCE CARRIERS 34 08 RESTRICT PATIENT RECRUITMENT ON A RANDOMIZED CLINICAL TRIAL: EXPERIENCE OF 95 U.S. PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) ON THE SCOT TRIAL
K. SULLIVAN, J. SEIBOLD, M. MAYES, M.E. CSUKA, R. NASH, R. SIMMS, D. FURST
SP.02.2 AMIFOSTINE ADDITION TO CONDITTIONIG REGIMEN IN AUTOLOGOUS STEM CELL 52 09 TRANSPLANTATION FOR SEVERE SYSTEMIC SCLEROSIS
E. REYES, LM. AVILA-PORTILLO, A. ARBELAEZ, B. OSPINO, DA. JAIMES, J. BELLO, J. LONDONO, R. VALLE
Page 26
SP.02.2 MIXED CONNECTIVE TISSUE DISEASE IN CHILDREN: PECULIAR CLINICAL 73 10 FEATURES AND FOLLOW-UP ANALYSIS OF METHOTREXATE’ DISEASE-MODIFYING TREATMENT. M.K. Osminina, N.A. Geppe, G.M. Rabieva, J.O. Kostina, G.V. Tugarinova
SP.02.2 A CASE OF BOSENTAN TREATMENT IN SYSTEMIC SCLEROSIS PATIENT WITH 83 11 SUDDEN BLINDNESS DUE TO OPTIC DISC ISCHEMIA
S. NAH, SANG IL. Mo, HYUN-SOOK. Kim
SP.02.2 PILOT STUDY OF INTENSE PULSED LIGHT (IPL) FOR THE TREATMENT OF 91 12 SYSTEMIC SCLEROSIS-RELATED TELANGIECTASES
T. MOORE, A K. Murray, H. Richards, H. Ennis, C. Griffiths, A L. Herrick
SP.02.2 SIMVASTATIN IN SYSTEMIC SCLEROSIS PATIENTS – AN OPEN-LABEL STUDY 102 13
R.C. Ionitescu, C. Mihai, M. Bojinca, R. Sfrent- Cornateanu, A. Ion, L. Macovei, O. Manea, M. Sasu, I. Ancuta, M. Milicescu, C. Mogosan, M. Abobului, F. Berghea, D. Predeteanu, R. Ionescu, V. Stoica
SP.02.2 CYTOKINE MEASUREMENT BEFORE AND AFTER HEMATOPOIETIC STEM CELL 103 14 TRANSPLANTATION IN SEVERE DIFFUSE SYSTEMIC SCLEROSIS.
JAAP. VAN LAAR, DOMINIQUE. FARGE(,), JULIE. BARAUT, FRANCETTE. JEAN-LOUIS, E.W.N. ROMIJN, J. VAN PELT, E.W.N. LEVARHT, HOMA. KESHTMAND, FRANCK. VERRECCHIA, LAURENCE. MICHEL
SP.02.2 LONG-TERM OUTCOME WITH FIRST-LINE BOSENTAN THERAPY IN SYSTEMIC 126 15 SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
D. LAUNAY, O. Sitbon, J. Le Pavec, L. Savale, C. Tcherakian, A. Yaici, L. Achouh, F. Parent, X. Jaïs, G. Simonneau, M. Humbert
SP.02.2 ANTI-FIBROTIC EFFECTS OF CYCLOPHOSPHAMIDE ON BLEOMYCIN-INDUCED 133 16 EXPERIMENTAL SCLERODERMA
M. OZGEN, S. KOCA, B. USTUNDAG, I. OZERCAN, F. DAGLI, A. ISIK
SP.02.2 BOSENTAN IN ACRAL ISCHEMIA NOT RELATED TO SCLERODERMA. 165 17
F. HAFNER, H. FROEHLICH, T. GARY, S. PAETZOLD, K. STEIDL, E. PILGER, M. BRODMANN
Page 27
SP.02.2 THE EFFECT OF A SINGLE LINE THERAPY WITH BOSENTAN VERSUS A 166 18 SEQUENTIAL THERAPY OF PROSTANOIDS AND BOSENTAN IN THE TREATMENT OF DIGITAL SKIN ULCERS IN SEVERE SCLERODERMA F. HAFNER, T. GARY, H. FROEHLICH, S. PAETZOLD, K. STEIDL, E. PILGER, M. BRODMANN
SP.02.2 INHIBITING B-CELL ACTIVATION BY SKIN FIBROBLASTS AND PULMONARY 178 19 EPITHELIAL CELLS: A NEW TREATMENT FOR SYSTEMIC SCLEROSIS ?
A. FRANCOIS, I. COUILLIN, D. WACHSMANN, J. SIBILIA, JE. GOTTENBERG
SP.02.2 TREATING MILD PULMONARY VASCULAR DISEASE ASSOCIATED WITH SYSTEMIC 189 20 SCLEROSIS LEADS TO FAVOURABLE OUTCOMES.
N. DWYER, J. WALSH, D. KILPATRICK(,), J. ZOCHLING
SP.02.2 ALPROSTADIL AND SILDENAFILA IN THE TREATMENT OF VASCULAR 195 21 COMPLICATIONS OF SYSTEMIC SCLEROSIS
E. DO ROSÁRIO E SOUZA, F. SILVA, P. MADUREIRA
SP.02.2 EVIDENCE OF SKIN REMODELING AND IMPROVEMENT OF LUNG FUNCTION 215 22 FOLLOWING 2 YEARS OF RITUXIMAB TREATMENT IN A PATIENT WITH DIFFUSE SCLERODERMA.
D. DAOUSSIS, S.N. LIOSSIS, A. TSAMANDAS, C. SIRINIAN, C. KALOGEROPOULOU, A. KAZANTZI, G. YIANNOPOULOS, A. ANDONOPOULOS
SP.02.2 IMPROVEMENT OF LUNG FUNCTION AND SKIN THICKENING FOLLOWING LONG 216 23 TERM RITUXIMAB TREATMENT IN PATIENTS WITH SCLERODERMA.
D. DAOUSSIS, S.N. Liossis, C. Kalogeropoulou, A. Kazantzi, G. Yiannopoulos, A. Andonopoulos
SP.02.2 MULTIMODAL THERAPY FOR ACE-INHIBITOR REFRACTORY SCLERODERMA 228 24 RENAL CRISIS WITH BIOPSY PROVEN THROMBOTIC ANGIOPATHY
B. Hegner, B. Rudolph, R. Schindler, F.C. Luft, G. Riemekasten, D. Dragun
SP.02.2 SAFETY OF LONG TERM BOSENTAN TREATMENT IN CONNECTIVE TISSUE 231 25 DISEASES
S. Melchor, BE. Joven, PE. Carreira
Page 28
SP.02.2 VACUUM ASSISTED CLOSURE THERAPY: A NOVEL TREATMENT FOR 237 26 REFRACTORY DIGITAL ULCERATION IN SYSTEMIC SCLEROSIS S. BROWN, J. James, JD. Pauling, JA. Shipley, E. Korenodwych, NJ. McHugh(,)
SP.02.2 ANTIINFLAMMATORY AND ANGIOPROTECTIVE EFFECTS OF ATORVASTATIN 273 27 TREATMENT OF SYSTEMIC SCLEROSIS
R. ALEKPEROV, E. G. Lyubimova, E. N. Alexandrova, A. A. Novikov
SP.02.2 PREDICTIVE FACTORS TO RESPOND TO PULSED INTRAVENOUS 279 28 CYCLOPHOSPHAMIDE IN PATIENTS WITH SYSTEMIC SCLEROSIS – RESULTS FROM A SINGLE CENTRE STUDY
A. Schohe, M. Becker, D. Huscher, U. Schneider, K. Hanke, G.R. Burmester, G. Riemekasten
SP.2.22 HIGH DOSES VENOUS IMMUNOGLOBULIN G THERAPY SIMULTANELOUSLY WITH 286 9 AZATHIOPRINE TO PATIENTS WITH SCLEROMYOSITIS
S. VLADEVA
SP.02.2 COLOMBIAN EXPERIENCE WITH AUTOLOGOUS HAEMATOLOGICAL STEM CELL 289 30 TRANSPLANTATION IN SEVERE AND REFRACTORY SYSTEMIC SCLEROSIS: TWO CASE-REPORT
C. VELASQUEZ, M. VELASQUEZ, L.A. RAMIREZ
SP.02.2 CALCITONIN INFUSIONS IN SYSTEMIC SCLEROSIS – CLINICAL EFFECTS IN A 294 31 RETROSPECTIVE STUDY
M. STICHERLING, LAURA. Schmitz, CORNELIA. Erfurt-Berge
SP.02.2 POSSIBLE IMMUNOLOGICAL EFFECTS OF ILOPROST - MODULATION OF ADHESION 295 32 MOLECULES AND T-CELL PROLIFERATION IN PATIENTS WITH SYSTEMIC SCLEROSIS
M. STICHERLING, PHILIPP. Rehberger
SP.02.2 EFFICACY OF COMBINATION THERAPY WITH ILOPROST AND BOSENTAN IN THE 299 33 TREATMENT OF SYSTEMIC SCLEROSIS.
V. MACRI', M. VASILE, I. SCIARRA, K. STEFANANTONI, A. SPADARO, F. CECCARELLI, V. RICCIERI, G. VALESINI
Page 29
SP.02.2 SECTION OF EXTERNAL LATERAL CAPSULAR LIGAMENT FOR THE TREATMENT OF 313 34 REDUCED MOUTH OPENING IN A SSC PATIENT. D. MELCHIORRE, M. GIANNINI, M. MARESCA, G. SALVADORINI, S. BELLANDO RANDONE, M. MATUCCI-CERINIC
SP.02.2 THERAPEUTIC STRATEGY COMBINING INTRAVENOUS CYCLOPHOSPHAMIDE 317 35 FOLLOWED BY ORAL MYCOPHENOLATE MOFETIL TO TREAT SEVERE OR WORSENING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS.
AL. DUCHANGE, L. MOUTHON, A. BEREZNE, S. MORELL-DUBOIS, PY. HATRON, L. GUILLEVIN, E. HACHULLA, D. LAUNAY
SP.02.2 AUTOLOGOUS MESENCHYMAL STEM CELLS (MSCS) FOSTER RE-GENERATION OF 321 36 THE VASCULAR NETWORK IN A SSC PATIENT WITH GANGRENE OF THE EXTREMITIES.
S. GUIDUCCI, I. MINIATI, R. SACCARDI, B. MAZZANTI, S. DAL POZZO, A. BOSI, F. PORTA, G. FIORI, M. MATUCCI-CERINIC
SP.02.2 VITAMIN E GEL REDUCES TIME TO HEALING OF DIGITAL ULCERS (DU) IN 326 37 SYSTEMIC SCLEROSIS
G. FIORI(/), F. GALLUCCIO(/), L. AMANZI, F. BRASCHI, I. MINIATI, ML. CONFORTI, A. DEL ROSSO, A. CANDELIERI, A. MAGONIO, R. GORETTI, L. RASERO, M. MATUCCI-CERINIC(/)
SP.02.2 PERCUTANEOUS ENDOSCOPIC GASTROSTOMY IN PATIENTS WITH SYSTEMIC 328 38 SCLEROSIS
L. FYNNE, A. Kruse, M. Borre, K. Soendergaard, K. Krogh
SP.02.2 NEW ONSET OF MYASTHENIA GRAVIS AFTER TREATMENT OF SYSTEMIC 329 39 SCLEROSIS BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: SUSTAINED AUTOIMMUNITY OR INADEQUATE RESET OF TOLERANCE ?
D. FARGE, C. deligny, E. Clave, T. Daikeler, D. Sibon, H. Keshmandt, M. Carmagnat, C. Douay, S. Arfi, B. Clair, A. Toubert
SP.02.2 NO CHANGE IN THE COURSE OF SYSTEMIC SCLEROSIS WITH IMATINIB MESYLATE 332 40
ISMAIL. SIMSEK, HAKAN. ERDEM, SEDAT. YILMAZ, SALIH. PAY, AYHAN. DINC
SP.02.2 MYCOPHENOLATE MOPHETIL IN THE TREATMENT OF SYSTEMIC 337 41 SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSC-ILD) IN PATIENTS UNRESPONSIVE TO CYCLOPHOSPHAMIDE (CYC)
G. CUOMO, G. Abignano, M. Iudici, A. Petrillo, G. Valentini
Page 30
SP.02.2 ENDOTHELIAL DYSFUNCTION AND INFLAMMATION MARKERS DYNAMICS DURING 346 42 ATORVASTATIN TREATMENT IN SYSTEMIC SCLEROSIS. R. ALEKPEROV, E. G. Lyubimova, E. N. Alexandrova, A. A. Novikov
SP.02.2 ACENOCOUMAROL IN THE TREATMENT OF CALCINOSIS IN SYSTEMIC SCLEROSIS. 347 43 CLINICAL ASSESSMENT USING 99MTC-HDP WHOLE-BODY SCINTIGRAPHY
J. ALEGRE SANCHO, E. Caballero Calabuig, J.A. Roman Ivorra, E. Beltran Catalan, J. Ivorra Cortes, N. Fernandez-Llanio Comella, C. Chalmeta Verdejo, E. Valls Pascual, I. Martinez Cordellat
SP.02.2 PARENTERAL NUTRITION IN SEVERE GASTROINTESTINAL MANIFESTATION OF 348 44 SCLERODERMA
S. ADLER, P. Villiger
SP.2.24 SAFETY OF LOW-DOSE CYCLOPHOSPHAMIDE PULSE THERAPY IN THE 349 5 TREATMENT OF SYSTEMIC SCLEROSIS
G. ABIGNANO, M. IUDICI, A. PETRILLO, G. CUOMO, G. VALENTINI
SP.2.24 BOSENTAN & SITAXENTAN IN THE TREATMENT OF PULMONARY ARTERIAL 359 6 HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
C. Valerio, C. Handler, CP. Denton, JG. Coghlan
SP.2.24 EFFICACY OF RITUXIMAB IN 2 PTS SUFFERING FROM SSC WITH SEVERE SKIN, 372 7 ESOPHAGEAL AND LUNGS INVOLVEMENT-PRELIMINARY RESULTS
J. Scali, S. Visentini, H. Scherbarth
SP.2.24 RAYNAUD'S CLINICS: DEALING WITH DIGITAL ULCERS 41 8
I. SILVA, I. ALMEIDA, C. VASCONCELOS
SP.2.24 THE ANTI-ANGIOGENIC FACTOR GUANYLATE BINDING PROTEIN-1 (GBP-1) IN 46 9 SYSTEMIC SCLEROSIS PATIENTS
M. SCARSI, L. ANDREOLI, P. AIRò, M. HERRMANN, M. STURZL, E. NASCHBERGER
SP.2.25 LASER DOPPLER PERFUSION IMAGING AND PHOTOPLETISMOGRAPHY ARE 50 0 USEFUL IN THE CHARACTERIZATION OF SCLERODERMIC RAYNAUD'S PHENOMENON
E. ROSATO, C. ROSSI, S. PISARRI, F. SALSANO
Page 31
SP.2.25 QUANTIFICATION OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS: 76 1 VERIFICATION OF THE EUSTAR RECOMMENDATIONS Y. OKAZAKI, T. SATOH, H. YASUOKA, M. KUWANA
SP.2.25 SCLERODERMA IN ASSOCIATION WITH VON WILLEBRAND DISEASE AND 86 2 PEYRONIE’S DISEASE - CASE REPORT
C. MÜLLER, V. SERRATO, T. MALUCELLI, E.S. PAIVA, V.F. AZEVEDO, S.C. RADOMINSKI
SP.2.25 COMPARISON OF CHANGES IN NAILFOLD CAPILLAROSCOPY AND RETINAL 90 3 ABNORMALITIES IN PATIENTS WITH SYSTEMIC CONNECTIVE TISSUE DISEASES.
E. MORGIEL, G. Wiland, P. Wiland
SP.2.25 A TWO YEAR PROSPECTIVE STUDY OF CHANGES IN NAILFOLD CAPILLARY 92 4 ARCHITECTURE IN PRIMARY AND SECONDARY RAYNAUD’S PHENOMENON.
A L. Herrick, T L. Moore, A K. Murray, A. Vail, C. Taylor
SP.2.25 EVIDENCE OF REDUCED NITRIC OXIDE AND PROSTACYCLIN ACTIVITY IN THE SKIN 95 5 MICROCIRCULATION OF PATIENTS WITH SSC MAY EXPLAIN IMPAIRMENT OF ENDOTHELIAL FUNCTION
A. MITCHELL, PRIV.-DOZ., U. Rushentsova, A. Kribben
SP.2.25 ENDOTHELIN-1-RECEPTOR-ANTAGONISM IMPROVES SKIN PERFUSION IN 96 6 PATIENTS WITH SYSTEMIC SCLEROSIS
U. Rushentsova, T. Philipp, A. Kribben, A. Mitchell
SP.2.25 AGONIST-STIMULATED VASODILATION CORRELATES WITH LEVELS OF 97 7 ANTINUCLEAR ANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS – INVESTIGATIONS IN THE SKIN MICROCIRCULATION
U. Rushentsova, T. Philipp, A. Kribben, A. Mitchell
SP.2.25 ENDOTHELIUM–DEPENDENT VASODILATION IN PATIENTS WITH SYSTEMIC 98 8 SCLEROSIS CORRELATES WITH AUGMENTATION INDEX – INVESTIGATIONS IN THE SKIN MICROCIRCULATION AND PULSE WAVE ANALYSIS
U. Rushentsova, T. Philipp, A. Kribben, A. Mitchell
Page 32
SP.2.25 PERIPHERAL ARTERY DISEASE IN SYSTEMIC SCLEROSIS 120 9 Y. ZENG, Y. YE, M. LI, D. XU, Y. HOU, Q. WANG, X. ZENG
SP.2.26 INCREASED PRODUCTION OF PROSTAGLANDIN E2 (PGE2) IN THE PERPHERAL 127 0 BLOOD MONONUCLEAR CELLS (PBMC) FROM PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (SSC).
A. LAPINSKA, M. BIELECKI, K. KOWAL, O. DISTLER, J. CHWIECKO, I. DOMYSLAWSKA, S. SIERAKOWSKI, J. SKOWRONSKI, L. CHYCZEWSKI, S. GAY, O. KOWAL-BIELECKA
SP.2.26 COMPARISON OF CAPILLAROSCOPIC FINDINGS AT FINGERS AND TOES IN 128 1 SYSTEMIC SCLEROSIS
S. LAMBOVA, W. Hermann, U. Mueller-Ladner
SP.2.26 ASSOCIATION BETWEEN CAPILLAROSCOPIC CHANGES IN SYSTEMIC SCLEROSIS 129 2 PATIENTS AND PRESENCE OF DIGITAL ULCERS
S. LAMBOVA, ULF. Mueller Ladner
SP.2.26 CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 LEVELS ARE 130 3 ELEVATED AND CORRELATED WITH ENDOTHELIN-1 IN PATIENTS WITH SYSTEMIC SCLEROSIS
S.H. Park, S.K. Kwok
SP.2.26 ADIPONECTIN AND VASPIN LEVELS IN SYSTEMIC SCLEROSIS 135 4
M. Ozgen, S. Koca, B. Isik, N. Dagli, B. Ustundag, A. Isik
SP.2.26 SERUM SALUSIN-ALPHA LEVEL IN SYSTEMIC SCLEROSIS 136 5
M. Ozgen, S. Koca, B. Isik, N. Dagli, B. Ustundag, A. Isik
SP.2.26 NAILFOLD CAPILLARY DIMENSION CORRELATED WITH PLASMA ENDOTHELIN 137 6 LEVEL IN SYSTEMIC SCLEROSIS
H. KIM, S. Nah, S. Park
Page 33
SP.2.26 ROLE OF AGONISTIC AUTOANTIBODIES DIRECTED TO THE ANGIOTENSIN II TYPE 1 138 7 AND THE ENDOTHELIN-1 TYPE A RECEPTORS IN SYSTEMIC SCLEROSIS A. KILL, M. Becker, J. Günther, C. Jessen, D. Dragun, G.R. Burmester, G. Riemekasten
SP.2.26 FUNCTIONAL AND MORPHOLOGICAL EVALUATION OF THE DIGITAL 143 8 MICROCIRCULATION WITH LASER DOPPLER IMAGING, FINGERTIP LACTICEMY TEST AND NAILFOLD CAPILLAROSCOPY IN SYSTEMIC SCLEROSIS
C. KAYSER, M.J.U. CORREA, L.E.C. ANDRADE
SP.2.26 IMPROVING OUTCOME PREDICTION OF SYSTEMIC SCLEROSIS FROM ISOLATED 149 9 RAYNAUD’S PHENOMENON: ROLE OF AUTOANTIBODIES AND NAILFOLD CAPILLAROSCOPY
F. INGEGNOLI, R. Gualtierotti, P. Boracchi, E.M. Biganzoli, S. Zeni, C. Lubatti, F. Fantini
SP.2.27 AN EXPLORATION AND ANALYSIS OF THE CURRENT APPROACH TO 152 0 ISCHEMICALLY THREATENED DIGIT
A. IMPENS, T. Win, K. Phillips, E. Schiopu, J. Seibold
SP.2.27 CHINA NAILFOLD CAPILLARY MICROSCOPY SCORE IN SYSTEMIC SCLEROSIS 158 1
Y. HOU, M. Li, D. Xu, Q. Wang, X. Zeng, F. Zhang
SP.2.27 ANGIOTENSIN AND ENDOTHELIN RECEPTOR EXPRESSION IN PERIPHERAL 168 2 IMMUNE CELLS FROM HEALTHY DONORS AND SYSTEMIC SCLEROSIS (SSC) PATIENTS
J. GUENTHER, A. Kill, M.O. Becker, R. Widmer, K. Hanke, D. Dragun, G. Riemekasten
SP.2.27 FINGER THERMOREGULATORY MODEL ASSESSING FUNCTIONAL IMPAIRMENT IN 170 3 RAYNAUD’S PHENOMENON
A. Mariotti, G. Grossi, P. Amerio, A. Merla, G. Orlando, A. Tulli, GL. Romani
SP.2.27 FUNCTIONAL INFRARED IMAGING OF PAROXYSMAL ISCHEMIC EVENTS IN 171 4 PATIENTS WITH RAYNAUD'S PHENOMENON
P. Amerio, G. Grossi, A. Merla, A. Mariotti, A. Carbone, A. Tulli, GL. Romani
Page 34
SP.2.27 MICROSCOPIC POLYANGIITIS ASSOCIATED WITH CREST SYNDROME: A 175 5 DIFFICULT CLINICAL CHALLENGE S. GINDEA, L. Jan
SP.2.27 MACROVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS – 190 6 PREDICTIVE RISK FACTOR FOR SEVERE DIGITAL VASCULOPATHY
C.M. Tanaseanu, ST. Tanaseanu, A. Dumitrascu, I. Tiglea, M. Popescu, M. Parvu, E. Moldoveanu
SP.2.27 SERUM LACTATE DEHYDROGENASE ACTIVITY – A POSSIBLE PARAMETER FOR 191 7 VASCULAR INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
C.M. Tanaseanu, ST. Tanaseanu, A. Dumitrascu, I. Tiglea, M. Popescu, M. Parvu, E. Moldoveanu
SP.2.27 INFLAMMATORY CHEMOKINES IN SYSTEMIC SCLEROSIS 220 8
V. Codullo(,), C. Bonino, A. Gilmour, B. Xoxi, I B. McInnes, C. Montecucco, G J. Graham
SP.2.27 SIGNALING INDUCED BY ENDOGENOUS LIGAND INDEPENDENT AUTOIMMUNE 227 9 ACTIVATION OF ANGIOTENSIN TYPE 1- AND ENDOTHELIN TYPE A-RECEPTOR IN MICROVASCULAR ENDOTHELIAL CELLS
M. Naether, A. Philippe, R. Catar, I. Lukitsch, G. Riemekasten, D. Dragun
SP.2.28 NAILFOLD CAPILLAROSCOPY FINDINGS IN PATIENTS WITH RAYNAUD´S 250 0 PHENOMENON
E. BELTRAN-CATALAN, E. VALLS, J.A. ROMAN, J.J. ALEGRE, J. IVORRA, N. FERNANDEZ-LLANIO, C. CHALMETA, I. MARTINEZ
SP.2.28 LIPID PROFILE AND PRO-THROMBOTIC DISORDER IN SYSTEMIC SCLEROSIS 264 1
C. ANCUTA, C. POMIRLEANU(,), E. ANCUTA, C. IORDACHE, C. BELIBOU, R. CHIRIEAC(,)
SP.2.28 IMPACT OF DIGITAL ULCERS ON OCCUPATIONAL AND PROFESSIONAL ACTIVITY 283 2 IN SYSTEMIC SCLEROSIS
A. BEREZNE, R. SEROR, S. MORELL-DUBOIS, M. DE MENTHON, E. FOÏS, A. DZIENG-ELLA, FRÉDÉRIQUE. DUPUIS, LOÏC. GUILLEVIN, SERGE. POIRAUDEAU, LUC. MOUTHON
SP.2.28 HAND RADIOLOGICAL DAMAGE IN SYSTEMIC SCLEROSIS: CLINICAL AND 290 3 FUNCTIONAL CORRELATIONS.
M. VANTHUYNE, J. Malghem, V. Smith, S. Arat, E. Delanghe, G. Depresseux, F. De Keyser, R. Westhovens, F.A. Houssiau, S. Koutaissoff
Page 35
SP.2.28 CORRELATION BETWEEN PERIPHERAL BLOOD PERFUSION AND 292 4 MICROVASCULAR ABNORMALITIES IN SYSTEMIC SCLEROSIS A. Sulli, C. Ferrone, C. Pizzorni, M.E. Secchi, S. Paolino, B. Seriolo, M. Cutolo
SP.2.28 EFFECTS OF PROSTACYCLIN TREATMENT ON BOTH NAILFOLD 293 5 MICROANGIOPATHY AND PERIPHERAL BLOOD PERFUSION IN SYSTEMIC SCLEROSIS
A. Sulli, C. Pizzorni, C. Ferrone, M.E. Secchi, S. Paolino, G. Zampogna, B. Seriolo, M. Cutolo
SP.2.28 RELIABILITY OF THE QUALITATIVE AND SEMIQUANTITATIVE NAILFOLD 296 6 VIDEOCAPILLAROSCOPY ASSESSMENT IN A SYSTEMIC SCLEROSIS COHORT: A BI-CENTRE STUDY
V. SMITH, C. PIZZORNI, F. DE KEYSER, S. DECUMAN, J. VAN PRAET, E. DE SCHEPPER, A. SULLI, M. CUTOLO
SP.2.28 ASSOCIATION OF NAILFOLD CAPILLAROSCOPY ABNORMALITIES AND MORTALITY 318 7 IN SYSTEMIC SCLEROSIS
SP.2.28 POSSIBLE RISK FACTORS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS 320 8
I. HERRGOTT, J. Gerß, C. Sunderkoetter, the DNSS centers
SP.2.28 DIGITAL ULCERS (DU) IN SYSTEMIC SCLEROSIS (SSC): STAGING, 327 9 CHARACTERISTICS AND SUB-SETTING THROUGH OBSERVATION OF 1614 DIGITAL LESIONS
F. GALLUCCIO, G. FIORI, L. AMANZI, F. BRASCHI, I. MINIATI, S. GUIDUCCI, ML. CONFORTI, O. KALOUDI, F. NACCI, O. SACU, A. CANDELIERI, A. MOGGI PIGNONE, L. RASERO, D. CONFORTI, M. MATUCCI-CERINIC
SP.2.29 OXIDATIVE DNA DAMAGE IN SYSTEMIC SCLEROSIS 350 0
M. TIKLY, X. Masoka, N. Matiwane, M. Gulumian
SP.2.29 STUDY ON CAPILLAROSCOPIC PATTERNS AND CLINICAL FINDINGS IN PATIENTS 353 1 WITH SYSTEMIC SCLEROSIS.
U. Jafiszow, S. Sierakowski, O. Kowal-Bielecka
Page 36
SP.2.29 HIGH FREQUENCY ULTRASOUND OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS 365 2 REFLECTS OEDEMA, EXTENSION AND SEVERITY IN EARLY DISEASE ROGER. Hesselstrand, MARIE. Wildt, AGNETA. Scheja
SP.2.29 SERUM LEVELS OF ANGIOPOIETIN-1 AND -2 IN PATIENTS WITH SYSTEMIC 369 3 SCLEROSIS
D. Krasowska, M. Michalska-Jakubus, G. Chodorowska,, M. Kowal
SP.2.29 ENDOTHELIAL MICROPARTICLES AS MARKERS OF MICROANGIOPATHY IN 370 4 SYSTEMIC SCLEROSIS.
D. Krasowska, M. Michalska-Jakubus, G. Chodorowska
SP.2.29 SCLERODERMA: HAND RADIOLOGY TALKS 67 5
C. PAMFIL, I. Filipescu, C. Bolosiu, S. Rednic
SP.2.29 ULTRASONOGRAPHIC FINGER JOINT EXAMINATION OF THE HAND IN SYSTEMIC 116 6 SCLEROSIS PATIENTS: PRELIMINARY RESULTS.
L. MANCARELLA, M. Battaglia, O. Addimanda, M. Di Carlo, S. Galletti, R. Meliconi
SP.2.29 ULTRASONOGRAPHY AND PLAIN RADIOGRAPHY IN THE ASSESSMENT OF 148 7 MUSCULOSKELETAL HAND INVOLVEMENT IN SYSTEMIC SCLEROSIS
F. INGEGNOLI, A. SOLDI, R. GUALTIEROTTI, V. GALBIATI, A. INGEGNOLI, P. BORACCHI, F. FANTINI, S. ZENI
SP.2.29 HAND IMPAIRMENT IN SYSTEMIC SCLEROSIS: EVALUATION BY MEANS OF 150 8 DIFFERENT HAND INDICES
F. INGEGNOLI, R. Gualtierotti, P. Boracchi, F. Ambrogi, V. Galbiati, A. Soldi, S. Zeni, F. Fantini
SP.2.29 RESSEGUIER METHOD AS A NOVEL TOOL TO IMPROVE QUALITY OF LIFE AND 204 9 PAIN IN SYSTEMIC SCLEROSIS (SSC) PATIENTS: PRELIMINARY RESULTS
S. Maddali-Bongi, A. Del Rosso, C. Di Felice, G. Landi, F. Galluccio, M. Matucci-Cerinic
SP.2.30 MANUAL LYMPH DRAINAGE IMPROVES UPPER LIMB EDEMA AND HAND 205 0 FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) IN EDEMATOUS PHASE
A. DEL ROSSO, S. MADDALI-BONGI, M. PASSALACQUA, S. MICCIO, M. MATUCCI CERINIC
Page 37
SP.2.30 EFFICACY OF A DISTRICT-SPECIFIC AND GLOBAL REHABILITATIVE 208 1 REHABILITATION PROGRAM TAILORED FOR SYSTEMIC SCLEROSIS PATIENTS: A PILOT STUDY S. Maddali-Bongi, A. Del Rosso, F. Galluccio, G. Tai, F. Sigismondi, M. Passalacqua, G. Landi, ML. Conforti, I. Miniati, M. Matucci-Cerinic
SP.2.30 A COMBINED REHABILITATIVE PROGRAM IS EFFICACIOUS IN THE TREATMENT OF 209 2 HANDS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS
S. Maddali-Bongi, A. Del Rosso, F. Galluccio, F. Sigismondi, I. Miniati, ML. Conforti, M. Matucci Cerinic
SP.2.30 THE COMBINATION OF CONNECTIVE TISSUE MASSAGE, KABAT'S TECHNIQUE, 210 3 KINESITHERAPY AND HOME EXERCISE IS HELPFUL IN FACE REHABILITATION OF SYSTEMIC SCLEROSIS (SSC) PATIENTS
S. Maddali-Bongi, A. Del Rosso, G. Landi, F. Galluccio, I. Miniati, ML. Conforti, M. Matucci-Cerinic
SP.2.30 SONOGRAPHIC ASSESSMENT OF HAND JOINT AND TENDON INVOLVEMENT IN 30 222 4 PATIENTS WITH SYSTEMIC SCLEROSIS
E. CHATELUS, H. CHIFFLOT, V. CLAVERT, C. SORDET, J.E. GOTTENBERG, J. SIBILIA
SP.2.30 EARLY DETECTION OF MEDIAN NERVE CARPAL TUNNEL SYNDROME WITH 256 5 HIGH-RESOLUTION 18 MHZ ULTRASONOGRAPHY IN SYSTEMIC SCLEROSIS PATIENTS
F. BANDINELLI, O. KALOUDI, I. MINIATI, ML. CONFORTI, A. CANDELIERI, D. MELCHIORRE, M. MATUCCI CERINIC
SP.2.30 JOINT INVOLVEMENT AND RELATIONSHIPS WITH SYSTEMIC INFLAMMATION IN 259 6 THE EULAR SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR) DATABASE OF SYSTEMIC SCLEROSIS PATIENTS
J. AVOUAC, UA. Walker, A. Tyndall, A. Kahan, M. Matucci-Cerinic, Y. Allanore, and EUSTAR coauthors
SP.2.30 CALCINOSIS CUTIS AND CONNECTIVE TISSUE DISEASE 276 7
H. AL ATTIA
SP.2.30 JOINT INVOLVEMENT IN SYSTEMIC SCLEROSIS 278 8
A. ABDESSEMED, N. KHALDOUN, N. BRAHIMI, A. LADJOUZE
Page 38
SP.2.30 CALCINOSIS IN SYSTEMIC SCLEROSIS: IDENTIFICATION OF 4 DIFFERENT 297 9 SUBTYPES O. SACU, G. FIORI, F. BARTOLI, F. BRASCHI, L. AMANZI, V. DENARO, C. MULLER, M.L. CONFORTI, S. GUIDUCCI, M. MATUCCI CERINIC
SP.2.31 ASSESSMENT OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC) WITH 302 0 ULTRASOUND ELASTOGRAPHY
AM. Iagnocco, C. Perella, V. Riccieri, O. Kaloudi, F. Bandinelli, F. Porta, G. Valesini, M. Matucci Cerinic
SP.2.31 JUVENILE LOCALISED SCLERODERMA EVALUATED BY HIGH FREQUENCY 303 1 ULTRASOUND (US)
F. Falcini, O. Kaloudi, F. Porta, F. Nacci, F. Bandinelli, S. Guiducci, ML. Conforti, I. Miniati, M. Matucci Cerinic
SP.2.31 HIGH FREQUENCY ULTRASOUND : A RELIABLE METHOD TO MEASURE DIGITAL 319 2 DERMAL THICKNESS IN SYSTEMIC SCLEROSIS
O. KALOUDI, F. BANDINELLI, E. FILIPPUCCI, M.L. CONFORTI, I. MINIATI, S. GUIDUCCI, F. PORTA, A. CANDELIERI, D. CONFORTI, G. GRASSIRI, W. GRASSI, M. MATUCCI CERINIC
SP.2.31 VALIDITY AND RELIABILITY OF THE ITALIAN VERSION OF THE HAND MOBILITY IN 334 3 SCLERODERMA (HAMIS) SCALE
A. DEL ROSSO, S. MADDALI BONGI, I. MINIATI, F. GALLUCCIO, F. SIGISMONDI, G. LANDI, M. MATUCCI-CERINIC
SP.2.31 ULTRASONOGRAPHIC FEATURES OF THE HANDS AND WRISTS IN SYSTEMIC 374 4 SCLEROSIS
G. Cuomo, M. Zappia, G. Abignano, A. Petrillo, M. Iudici, G. Valentini
SP.2.31 SCLERODERMA-POLYMYOSITIS OVERLAP SYNDROME: A DESCRIPTIVE STUDY OF 21 5 A RARE SYNDROME.
M. Vonk, K. Bhansing, H. Knaapen, B. van Engelen, P. van Riel
SP.2.31 DISEASE ACTIVITY CRITERIA FOR PATIENTS WITH EARLY SYSTEMIC SCLEROSIS 23 6
M. VONK, D. Diaconu, C. Denton, G. Riemekasten, D. Farge, L. Czirjak, P. van Riel, F. van den Hoogen, J. Fransen
SP.2.31 GALLBLADDER FUNCTION IN SYSTEMIC SCLEROSIS: A CLINICAL PILOT STUDY 26 7
P. Saar, T. Schmeiser, U. Müller-Ladner, I. Tarner
Page 39
SP.2.31 DOES FETUIN-A HAVE A ROLE IN SYSTEMIC SCLEROSIS-ASSOCIATED 109 8 CALCINOSIS? B. MARASINI, L. BELLOLI, N. CARLO-STELLA, ML. BIONDI, G. BRAMBILLA, N. UGHI, M. MASSAROTTI
SP.2.31 ALTERED SALIVARY REDOX HOMEOSTASIS IN PATIENTS WITH SYSTEMIC 174 9 SCLEROSIS
M. GORNITSKY, H. Su, M. Baron, M. Benarroch, A.M. Velly, H.M. Schipper
SP.2.32 SYSTEMIC BRAIN-DERIVED NEUROTROPHIC FACTOR AND NERVE GROWTH 183 0 FACTOR BALANCE IN SYSTEMIC SCLEROSIS.
MC. Lise, A. Sparsa, F. Lalloué, K. Ly, H. Bezanahari, V. Loustaud-Ratti, G. Gondran, JM. Bonnetblanc, E. Vidal(,), MO. Jauberteau, AL. Fauchais(,)
SP.2.32 CHARACTERIZATION OF SYNOVIAL FLUID METABOLIC COMPOSITION IN 339 1 SCLERODERMA VS RHEUMATOID ARTHRITIS USING PROTON MAGNETIC RESONANCE SPECTROSCOPY
C. CIURTIN, M.V. COJOCARU
SP.2.32 COLLAGEN CROSS-LINKS IN SYSTEMIC SCLEROSIS. 49 2
J. ROVENSKY, R. Istok, L. Czirjak, M. Bély, M. Stancikova
